Key points from article :
California-based company Rubedo Life Sciences focuses on developing treatments that target senescent cells, which are old cells that can worsen inflammation and other age-related health problems.
Rubedo secured $40 million in funding to move their lead drug candidate (RLS-1496) into clinical trials; these trials will see if it can help people with chronic skin conditions like atopic dermatitis and psoriasis.
Unlike current skin treatments that only manage symptoms, RLS-1496 is designed to directly target the underlying cause of these conditions by eliminating problem cells.
Rubedo also hopes to develop treatments for lung diseases (like idiopathic pulmonary fibrosis), liver diseases, musculoskeletal problems, and even cancer using their technology.
The $40 million funding came from various investors, including Khosla Ventures and Ahren Innovation Capital.
Investors are excited about the potential of Rubedo's research to improve the quality of life for people as they age, potentially preventing or reversing age-related diseases.
